Bococizumab: Phase III data

Top-line data from the double-blind, international Phase III SPIRE-HR trial in 711 patients with primary hyperlipidemia or mixed dyslipidemia at high or

Read the full 225 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE